Genmab A/S (GNMSF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 3,720,000 | 3,121,000 | 2,392,025 | 2,066,652 | 1,349,486 |
| Cost of Goods | 238,000 | 143,000 | 32,815 | N/A | N/A |
| Gross Profit | 3,482,000 | 2,978,000 | 2,359,210 | 2,066,652 | 1,349,486 |
| Operating Expenses | 2,417,000 | 2,006,000 | 1,587,416 | 1,166,501 | 869,322 |
| Operating Income | 1,065,000 | 972,000 | 772,609 | 900,151 | 480,164 |
| Interest Expense | 269,000 | 291,000 | 136,778 | 96,288 | 111,688 |
| Other Income | 408,000 | 645,000 | 182,662 | 192,293 | 265,220 |
| Pre-tax Income | 1,204,000 | 1,326,000 | 818,492 | 996,156 | 633,695 |
| Income Tax | 241,000 | 193,000 | 186,582 | 214,241 | 155,123 |
| Net Income Continuous | 963,000 | 1,133,000 | 631,910 | 781,915 | 478,573 |
| Net Income | $963,000 | $1,133,000 | $631,910 | $781,915 | $478,573 |
| EPS Basic Total Ops | 15.50 | 17.66 | 9.68 | 11.96 | 7.32 |
| EPS Basic Continuous Ops | 15.49 | 17.65 | 9.68 | 11.96 | 7.32 |
| EPS Diluted Total Ops | 15.37 | 17.53 | 9.59 | 11.84 | 7.25 |
| EPS Diluted Continuous Ops | 15.36 | 17.52 | 9.59 | 11.85 | 7.25 |
| EPS Diluted Before Non-Recurring Items | 15.37 | 14.60 | 11.80 | 11.85 | 7.24 |
| EBITDA(a) | $1,136,000 | $1,032,000 | $815,443 | $951,411 | $519,621 |